Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Novartis’ Remibrutinib Poised to Redefine Treatment for Chronic Inducible Urticaria In a significant advancement for patients battling chronic inducible urticaria (CIndU), Novartis has announced overwhelmingly positive results from its Phase III RemIND trial of remibrutinib. The oral medication has demonstrated the potential to become the first targeted therapy for this debilitating condition, offering hope to … Read more